SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

Pacemaker and ICD battery life needs to be extended to last 25 years Replacing batteries can lead to life-threatening infections

New telehealth legislation getting support from all angles CONNECT for Health Act gaining bipartisan, industry traction

Calling for a more personalized approach to preventing breast and ovarian cancers Psychological and medical risks need to be considered

Exposing the secrets of voodoo dolls through X-ray Virtual autopsy yields forensic insights in Haitian voodoo crimes

Portable seizure device yields unexpected mood benefits to PTSD patients Reduced sleeplessness, depression and nightmares by 30 percent

MR-compatible cardiac device implants add significant value to patient care A first-of-its-kind study finds value providers may be drawn to

Proton therapy is best for the most common pediatric brain tumor: study Medulloblastoma side effects diminished relative to conventional therapy

PET/CT beats CT and bone scans for detecting metastatic prostate cancer: study PET imaging of prostate has 'exploded' over last two years

Stryker to buy Sage for $2.8 billion HAI prevention product line expected to complement Stryker's offerings

Mathematical tool for MR may predict chance of migraines in concussion patients Shannon entropy may be more accurate than fractional anistropy

Amyloid imaging lights up SNM 2012

by Loren Bonner , DOTmed News Online Editor
Presenters at the 59th annual SNM meeting in Miami Beach, Fla., unveiled an array of breakthrough research and new techniques to detect evidence of Alzheimer's in living patients -- including, possibly, in asymptomatic populations.

Researchers know that beta-amyloid plaque can build up in the brain several years before an individual shows any signs of dementia. And many scientists believe that this plaque can kill vital neural pathways that are responsible for language, memory and behavior.

Story Continues Below Advertisement

We want to buy your Siemens Symphony or Avanto MRI -- today!

Top Dollar Paid, Fixed or Mobile. Call our Siemens Specialist for a Quote today -- 212-558-6600 Ext. 250 DOTmed Certified



"Molecular imaging can detect signs of Alzheimer's disease many years before patients develop dementia. It can do this because it can target beta-amyloid," says Dr. Christopher Rowe, a lead investigator for the Australian Imaging, Biomarkers and Lifestyle study of aging and professor of nuclear medicine at Austin Hospital in Melbourne, Australia.

In one of the studies presented by Rowe's team, PET was combined with an F-18 imaging agent. Subjects who showed high levels of the tracer during imaging had an 80 percent chance of developing Alzheimer's within two years, according to study findings.

Research also found that beta-amyloid plaque in the brain was not only involved in the pathology of Alzheimer's disease but also preceded mild cognitive function.

"For those with mild memory problems who had a positive scan, 66 percent of these people progressed to dementia over three years. This compares to only 7 percent of those with a negative scan," says Rowe.

Rowe highlighted findings on this study at the meeting, which included 194 healthy elderly subjects, 92 subjects with mild cognitive impairment, and 70 subjects with Alzheimer's. C-11 Pittsburgh compound B (PiB) combined with PET was used to gauge amyloid burden in the brain.

"This is an opportunity to find the patient who has Alzheimer's and intervene with treatments as they become available," says Rowe.

He pointed out that being able to correctly identify which patients have Alzheimer's and which don't is a necessary stepping stone for developing potential drugs and therapies to treat the disease.

Alzheimer's can only be detected in a patient after death-- by studying postmortem brain samples with beta-amyloid plaque.

Currently, no reliable treatment exists for Alzheimer's patients and the screening tests that do exist are unreliable and limited in their ability to identify the disease early.

New biomarkers emerge

Any PET amyloid imaging test must begin with a biomarker. This year's SNM meeting presented some promising amyloid imaging agents in development that will help clinicians detect Alzheimer's in living patients.

Continue reading Amyloid imaging lights up SNM 2012...
  Pages: 1 - 2 - 3 >>

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2016 DOTmed.com, Inc.
ALL RIGHTS RESERVED